Today, we look at MacroGenics, a stock that had a big rally in its shares during the second quarter.

The company has several catalysts in 2H20, the most important of which is the December 18, 2020, PDUFA date for its HER2+ mAb candidate margetuximab.

With seven oncology assets in the clinic, MacroGenics merited a deeper dive.

READ FULL ARTICLE HERE